NCT07021573
Protoporphyrin Imaging in Multispectral Evaluation of Resections
Not Yet Recruiting · Not Applicable · Medical University Innsbruck · registry updated 2025-09-09
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Observational non-interventional investigation to evaluate the potential of multispectral imaging in improving tumor visualization.
Inclusion
- Age Requirement: Patients must be 18 years of age or older.
- Diagnosis: Patients with a preoperative diagnosis of a suspected high-grade glioma based demographics and MRI imaging.
- MRI Findings: Patients must meet one of the following criteria:
- Group 1: Suspected high-grade glioma with contrast enhancement on MRI (GBM-like).
- Group 2: Suspected high-grade glioma without contrast enhancement on MRI (LGG-like).
- Surgical Resection: Patients scheduled to undergo surgical resection of the tumor as part of standard treatment.
Exclusion
- Patients with a known allergy or contraindication to 5-aminolevulinic acid (5-ALA) or its components.
- Use of all other fluorescent markers.
- Patients with a history of porphyria or other disorders related to 5-ALA metabolism.
- Patients with recurrent gliomas or those who have received prior treatment for their current brain tumor, including surgery, radiotherapy, or chemotherapy.
- Pregnant or breastfeeding patients, due to potential risks associated with 5-ALA administration.
- Patients with severe comorbidities or other medical conditions that, in the investigator's opinion, would pose an unacceptable risk or compromise the safety of participation in the study.